Boston Scientific Corporation net sales up 1.5 % to USD 5.138B in Q3 2026
Boston Scientific (BSX) reported Q3 2026 net sales of $5.138B, up 1.5%. GAAP EPS was $0.40, down from $0.51 a year ago, while adjusted EPS was $0.73, slightly lower than the previous year. The company faced challenges, including a cybersecurity incident, but remains confident in its long-term strategy. Full-year net sales growth is now expected to be around 4.25% on a reported basis and 3.75% organically, with adjusted EPS projected between $3.16 and $3.18.
How this was made
The 30-second read
Why it matters
Updated FY net sales growth (reported ~4.25%, organic ~3.75%) and adjusted EPS ($3.16 to $3.18) plus Q4 net sales decline guidance (reported/organic ~-3.0% to -1.0%) are the key decision inputs for positioning into the next quarter.
Market read
This is a company-specific earnings and guidance update with explicit quarterly and full-year numbers that can drive near-term estimate revisions.
What to watch
The guidance includes both reported and organic measures and excludes certain acquisition/divestiture and FX impacts; traders may need to normalize for those adjustments when comparing to consensus.
Background
The piece summarizes Boston Scientific’s Q3 2026 results, discusses a cybersecurity incident affecting operations, and provides updated full-year and Q4 2026 guidance.
Ticker impact
Boston Scientific reported Q3 2026 net sales of $5.138B (+1.5%) and guided full-year 2026 net sales growth and adjusted EPS ranges.
Likely modest reaction as traders weigh slightly positive sales growth and updated full-year guidance against weaker GAAP EPS.
The article provides the company’s own quarterly results plus explicit full-year and Q4 2026 net sales and adjusted EPS guidance, which are direct inputs to near-term valuation and expectations.
Market effects
Medical device peers may see read-through on demand durability and regional mix, especially EMEA and LACA strength.
LACA outperformance (reported +16.0%) could influence regional sales expectations for device distributors and channel partners.
No direct macro or cross-asset linkage beyond general risk sentiment around healthcare earnings season.
Counterpoint
The headline sales growth is modest, while GAAP EPS fell year over year, implying margin or cost pressures may be masking underlying softness.
Key entities
- companyBoston Scientific Corporation
US-listed medical device company reporting Q3 2026 results and updating FY 2026 and Q4 2026 guidance.
- executiveMike Mahoney
Chairman and CEO cited regarding operational resilience following a cybersecurity incident.
